EBMT 2019 | Molecular techniques for monitoring MRD in AML

Name: Molecular techniques for monitoring MRD in AML
Uploaded: 2019-04-10T13:49:25.000Z
Duration: 6 min 39 s
Description: Torsten Haferlach, MD Munich Leukemia Laboratory, Munich, Germany, evaluates the different methods currently being used to monitor measurable residual disease (MRD) in acute myeloid leukemia (AML) patients. This video was recorder at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Torsten Haferlach • 10 Apr 2019

EBMT 2019

Acute Myeloid Leukemia Leukemia

Torsten Haferlach, MD Munich Leukemia Laboratory, Munich, Germany, evaluates the different methods currently being used to monitor measurable residual disease (MRD) in acute myeloid leukemia (AML) patients. This video was recorder at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.